The Parexel Podcast | Episode 6: The opportunity for biotechs in precision medicine

March 5, 2020

Within the past 20 years, the field of precision medicine has been transformed. For biotech companies, this new landscape holds tremendous promise for innovation. So, why aren’t more companies leveraging this approach? In this episode, Parexel precision medicine experts Angela Qu and Arlene Hughes join host Alberto Grignolo to discuss this conundrum, and what biotechs should be thinking about right from the start, to open up the opportunity for this approach to help bring innovation and new therapies to more patients.  

Previous Article
Understanding Department of Justice Enforcement Policies relating to FDA-Regulated Products
Understanding Department of Justice Enforcement Policies relating to FDA-Regulated Products

At the recent 2019 Enforcement, Litigation and Compliance Conference hosted by the Food and Drug Law ...

Next Article
What Influences the Compliance Culture at FDA?
What Influences the Compliance Culture at FDA?

The Office of Compliance (OC) in the Center for Drug Evaluation and Research (CDER) at the Food and D...